Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
---|
01/05/2011 | EP2270513A2 Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
01/05/2011 | EP2270191A1 Preparation of microbial oil containing polyunsaturated fatty acids |
01/05/2011 | EP2270177A1 Streptococcus pneumoniae proteins and nucleic acids |
01/05/2011 | EP2270176A1 Streptococcus pneumoniae proteins and nucleic acids |
01/05/2011 | EP2270175A1 Streptococcus pneumoniae proteins and nucleic acids |
01/05/2011 | EP2270171A2 Haemophilus influenzae antigens and corresponding DNA fragments |
01/05/2011 | EP2270049A2 Recombinant anti-interleukin-9-antibody |
01/05/2011 | EP2270048A2 Anti-NGF antibodies and methods using same |
01/05/2011 | EP2270027A1 Polypeptides having brain-localizing activity and uses thereof |
01/05/2011 | EP2270005A1 Prodrug of an ice inhibitor |
01/05/2011 | EP2269990A1 Heterocyclic compound |
01/05/2011 | EP2269980A1 Creatine amides, a method for the production thereof and an agent exhibiting a neuroprotective action |
01/05/2011 | EP2269654A2 Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties |
01/05/2011 | EP2269628A2 Pancreas-specific proteins |
01/05/2011 | EP2269609A2 Treatment of neurodegenerative diseases and cancer of the brain with SAHA |
01/05/2011 | EP2269608A2 Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor |
01/05/2011 | EP2269600A1 Treatment of sleep disorders using eplivanserin in COPD patients |
01/05/2011 | EP2269596A2 Use of adenosine A2a receptor antagonists for the treatment of extrapyramidal syndrome and other movement disorders |
01/05/2011 | EP2269595A1 Titratable dosage transdermal delivery system |
01/05/2011 | EP2269587A1 Controlled release hydrocodone formulations |
01/05/2011 | EP2269585A2 Once-a-day oxycodone formulations |
01/05/2011 | EP2269579A2 Tamper-resistant products for opioid delivery |
01/05/2011 | EP2269577A2 Injectable suspensions having improved injectability properties |
01/05/2011 | EP2269467A1 Pasteurisation process for microbial cells and microbial oil |
01/05/2011 | EP2268657A2 Histidine related compounds for identifying and blocking amyloid beta ion channels |
01/05/2011 | EP2268647A2 Compounds and compositions for the detection and treatment of alzheimer's disease and related disorders |
01/05/2011 | EP2268645A1 Substituted dihydro, trihydro and tetrahydro cycloalkyloxazolopyrimidinones, preparation and use thereof as allosteric modulators of mglur |
01/05/2011 | EP2268639A2 Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate |
01/05/2011 | EP2268638A1 Tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists |
01/05/2011 | EP2268636A1 Gamma secretase modulators |
01/05/2011 | EP2268632A1 Tertiary amine derivatives as phosphodiesterase-4 inhibitors |
01/05/2011 | EP2268631A1 Aminopiperidinyl derivatives and uses thereof |
01/05/2011 | EP2268628A1 2-aryl and 2 -heteroaryl 4h-1-benzopyran-4-one-6-amidino derivatives for the treatment of arthritis, cancer and related pain |
01/05/2011 | EP2268314A2 Use of pyrene to carry peptides across the blood brain barrier |
01/05/2011 | EP2268303A1 NOVEL USES OF VEGF xxxB |
01/05/2011 | EP2268280A2 Quinolizidinone m1 receptor positive allosteric modulators |
01/05/2011 | EP2268141A1 Compounds and method for reducing uric acid |
01/05/2011 | EP2268140A2 Novel compounds advantageous in the treatment of central nervous system diseases and disorders |
01/05/2011 | EP2094706B1 Substituted 2,5-dfflydro-3h-pyrazolo[4,3-c]pyridazin-3-one derivatives, preparation thereof and use of same as cannabinoid cb1 receptor ligands |
01/05/2011 | EP2076508B1 Biaryl ether urea compounds |
01/05/2011 | EP2029139B1 Use of a p38 kinase inhibitor for treating psychiatric disorders |
01/05/2011 | EP1948606B1 3, 5-disubstituted phenyl-piperidines as modulators of dopamine neurotransmission |
01/05/2011 | EP1908467B1 Agent for treating herpesvirus-derived pain |
01/05/2011 | EP1797088B1 Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
01/05/2011 | EP1558256B1 Pyrroloquinoline quinone and a beta blocker for the treatment of ischemia or reperfusion injury |
01/05/2011 | EP1542692B1 Aminopyrimidine derivatives for use as vanilloid receptor ligands for the treatment of pain |
01/05/2011 | EP1493034B1 Method for diagnosing inflammatory diseases and infections by the determination of lasp-1 immunoreactivity |
01/05/2011 | EP1463806B1 Novel cyclooxygenase variants and methods of use |
01/05/2011 | EP1437043B1 Rat model with overexpression of regucalcin |
01/05/2011 | EP1433480B1 Medicine containing pyrimidine derivative |
01/05/2011 | EP1128814B1 Aerosols comprising nanoparticle drugs |
01/05/2011 | EP1085862B1 Treatment of an autoimmune disease |
01/05/2011 | CN201692331U Equipment for preparing nano level pearl powder |
01/05/2011 | CN1927193B Use of agomelatine for the preparation of medicaments for the treatment of sleep disorders in depressed patients |
01/05/2011 | CN101939337A Anti-TRKA antibodies and derivatives thereof |
01/05/2011 | CN101939327A New macrolides and their use |
01/05/2011 | CN101939323A Pyrazolopyrimidines, a process for their preparation and their use as medicine |
01/05/2011 | CN101939321A Production method and production device for composition having high content of theobromine |
01/05/2011 | CN101939315A Gamma secretase modulators |
01/05/2011 | CN101939312A Gamma secretase modulators |
01/05/2011 | CN101939311A Heterocyclic compounds with affinity to muscarinic receptors |
01/05/2011 | CN101939306A Tosylate salt of trans-n-isobutyl-3-fluoro-3- [3-flu0r0-4- (pyrrolidin-1-yl-methyl) -phenyl] cyclobut anecarboxamide |
01/05/2011 | CN101939300A 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid CB1 receptor modulators |
01/05/2011 | CN101939297A Benzylpiperizine compound |
01/05/2011 | CN101939293A N-oxides of venlafaxine and O-desmethylvenlafaxine as prodrugs |
01/05/2011 | CN101939287A Crystalline modifications of (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl -propyl)-phenol |
01/05/2011 | CN101939055A 2-aminoquinolines |
01/05/2011 | CN101939017A Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
01/05/2011 | CN101939012A Macrolides for treating diseases mediated through PDE inhibition |
01/05/2011 | CN101939010A Sense-improving agent |
01/05/2011 | CN101939004A Delayed release pharmaceutical composition of duloxetine |
01/05/2011 | CN101938998A Controlled-release pharmaceutical formulation |
01/05/2011 | CN101935352A Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies |
01/05/2011 | CN101935334A Berberine glycyrrhetinic acid enantiomeric salts and preparation method and application thereof |
01/05/2011 | CN101935331A Novel 4,5-pyrazoline ring-containing helicid medicament with sedative activity and preparation method thereof |
01/05/2011 | CN101935322A Diazabicyclic central nervous system active agents |
01/05/2011 | CN101935301A Modulators of ATP-binding cassette transporters |
01/05/2011 | CN101934115A Health bamboo vinegar paste |
01/05/2011 | CN101934078A Pharmaceutical composition comprising drospirenone and estrogen, and application thereof |
01/05/2011 | CN101934069A Application of neuroglobin in promoting neurite growth |
01/05/2011 | CN101934057A Traditional Chinese medicine for treating schizophrenia |
01/05/2011 | CN101934053A Chinese herbal medicament for treating sciatica |
01/05/2011 | CN101934037A Edaravone injection and preparation process thereof |
01/05/2011 | CN101934034A Chinese herbal medicine for treating trigeminal neuralgia |
01/05/2011 | CN101934028A Quality control method for Chinese medicinal preparations for treating hyperkinetic syndrome of childhood |
01/05/2011 | CN101934017A Chinese herbal medicine for treating hereditary ataxia |
01/05/2011 | CN101934014A Nourishing type nutritional health-care wine |
01/05/2011 | CN101934008A Oral medicament for treating cerebral hemorrhage and cerebral thrombosis |
01/05/2011 | CN101934001A Medicament for treating rheumatic headache |
01/05/2011 | CN101933997A Compound anti-inflammatory antipruritic ointment |
01/05/2011 | CN101933963A Nasal in-situ gel for treating headache |
01/05/2011 | CN101933941A Protein-free pig blood extract water injection and preparation method thereof |
01/05/2011 | CN101933940A Application of pig blood deproteinized extract to cranial vascular disease |
01/05/2011 | CN101933933A Application of 2-fluoro-beta-D-glucoside in treating depression |
01/05/2011 | CN101933932A Application of 4-cyan-beta-D-glucoside in treating chronic neurogenic pain |
01/05/2011 | CN101933925A Huperzine A with abirritation and derivatives thereof |
01/05/2011 | CN101933913A Dexmethylphenidate hydrochloride dual-release preparation and preparation method thereof |
01/05/2011 | CN101933911A Soft capsule composition for treating senile dementia and preparation method thereof |
01/05/2011 | CN101933910A Mecobalamin soft capsule and preparation method thereof |
01/05/2011 | CN101933899A Edaravone injection and preparation method thereof |